William Blair analyst Sarah Schram initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating. The company is equipped with a “differentiated” large molecule transport vehicle platform to “reach peak potential,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics upgraded to Buy from Hold at Stifel
- Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
- Denali Therapeutics management to meet with B. Riley
- Denali Therapeutics Advances Brain Disease Therapies
- Denali Therapeutics sees Fy24 opex increase of 5%-10% year-over-year